A3P Biomedical appoints Anders Martin-Löf as new CFO

May 18, 2022

A3P Biomedical has appointed Anders Martin-Löf as Chief Financial Officer (CFO). Anders Martin-Löf brings more than 20 years’ experience from the life science industry, including CFO positions at Oncopeptides, Wilson Therapeutics and RaySearch Laboratories. He will take up his new position at A3P Biomedical in August and report to CEO David Rosén.

“I am very pleased that we have been able to recruit Anders Martin-Löf as our new CFO. With broad experience from the industry and several challenging CFO positions, Anders will be a great addition to the management team. Following our recent successfully completed private placement, we are now able to accelerate the commercial expansion of Stockholm3 and offer significantly improved prostate cancer diagnostics to more healthcare providers and men. I look forward to working closely with Anders and would also like to thank our board member Cecilia Edström for stepping in as acting CFO during the recruitment process,” says David Rosén CEO of A3P Biomedical.

“Stockholm3 can make a big difference in the fight against cancer and I believe that there is great potential both for patients and health-care providers in using it as standard of care for early detection of prostate cancer, the second most common cancer in men worldwide. I am really excited about joining A3P Biomedical and look forward to contributing to the global clinical roll-out, and increased patient and shareholder value,” says Anders Martin-Löf.

Anders Martin-Löf is 50 years old and holds an MSc in Engineering Physics, from the Royal Institute of Technology (KTH), and BA major in business administration, from the Stockholm and Uppsala Universities. Most recently, he has been CFO of Oncopeptides AB and prior to that, he served as CFO of Wilson Therapeutics AB and RaySearch Laboratories AB. Anders Martin-Löf also has experience from various commercial positions in the life science industry and as a management consultant at the Boston Consulting Group.

Anders Martin-Löf will take up his new position in mid-August and succeeds Cecilia Edström who has been acting CFO since February 2022.

About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com 

About Stockholm3

Stockholm3 is a blood-based test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml.  Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values.  Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 40-90% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 40-50% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about our clinical studies please visit www.a3p.com.

About prostate cancer

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

Press contact:
Cecilia Edström
cecilia.edstrom@a3p.com
+46 72 226 2328